News Room

Recent News

September 2022

Accelevir partners with Frontier Science Foundation to launch LDMS laboratory information system. This laboratory information management system supports the AIDS Clinical Trial Group (ATCG) testing program.


August 2022

Accelevir completes on-site Maryland State CLIA inspection.


April 2022

Accelevir partners with Boditech Med and the Immunostics Company (New Jersey, US) to access global manufacturing and distribution. Accelevir leverages its capabilities for Point of Care (POC) assays under a new entity QuickFhyrTM Health (Baltimore, MD).


February 2022

Accelevir enters into an Laboratory Network Agreement with Yale School of Public Health to offer SalivaDirectTM as a low cost saliva testing and surveillance program for COVID-19.


January 2021

Accelevir receives State of Maryland laboratory license and becomes a CLIA certified laboratory for high complexity testing.


October 2020

Accelevir issued US patent describing innovative methods for quantitative characterization of persistent HIV proviruses.


April 2020

Accelevir announces award of a multi-year NIH Cooperative Agreement to establish a centralized testing resource for HIV persistence.


September 2019

Accelevir receipt of NSF Phase IIB funding to support expanded ddPCR assay development and sequencing.



The effect of induction immunosuppression for kidney transplant on the latent HIV reservoir
JCI Insight | 2022 Nov

Single center, open label dose escalating trial evaluating once weekly oral ixazomib in ART-suppressed, HIV positive adults and effects on HIV reservoir size in vivo
EClinical Medicine | 2021 Nov

The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy
Science Translational Medicine | 2021 Jun

Shared Mechanisms Govern HIV Transcriptional Suppression in Circulating CD103+ and Gut CD4+ T Cells
Journal of Virology | 2020 Dec

Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus-1
Clinical Infectious Diseases | 2021 Jun

Nonstructured Treatment Interruptions Are Associated With Higher Human Immunodeficiency Virus Reservoir Size Measured by Intact Proviral DNA Assay in People Who Inject Drugs
Journal of Infectious Diseases | 2021 Jun

Distinct viral reservoirs in individuals with spontaneous control of HIV-1
Nature | 2020 Sept

Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy
Journal of Infectious Diseases | 2021 Feb

Intact proviral DNA assay analysis of large cohorts of people with HIV provides a benchmark for the frequency and composition of persistent proviral DNA
PNAS | 2020 Jul

Differential decay of intact and defective proviral DNA in HIV-1-infected individuals on suppressive antiretroviral therapy
JCI Insight | 2020 Feb

Elite suppressors have low frequencies of intact HIV-1 proviral DNA
AIDS | 2020 Mar

A quantitative approach for measuring the reservoir of latent HIV-1 proviruses
Nature | 2019 Feb


Accelevir | © 2023